arrow
R

Roland A. Cooper

Dominican University of California
H指数:34
被引数:5,930

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Potent acridone antimalarial against all three life stages of Plasmodium

针对疟原虫的所有三个生命阶段的有效acridone抗疟药

2026-04-140
OAAI
Optimization of Prodiginines as Single-Dose Curative Antimalarials

单剂量根治性抗疟药Prodiginines的优化

2025-11-010
PRE
Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance

在青蒿素部分耐药背景下鉴定下一代抗疟三氧杂环戊烷类药物

2025-08-080
OA
Plasmodium falciparum protein kinase 6 and hemozoin formation are inhibited by a type II human kinase inhibitor exhibiting antimalarial activity

Plasmodium falciparum蛋白激酶6和血红素晶体的形成被一种具有抗疟疾活性的II型人源激酶抑制剂所抑制

2025-07-070
PRE
Development of Next-Generation Antimalarial Acridones with Radical Cure Potential

下一代具有自由基治愈潜力的抗疟喹诺酮类化合物的发展

2025-04-030
PRE
Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission
2024-12-060
OAAI
The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh Plasmodium falciparum isolates

延长恢复环阶段存活试验是新鲜恶性疟原虫分离株青蒿素敏感性表型的可扩展替代方法

2024-12-050
PRE
Tambjamines as Fast-Acting Multistage Antimalarials
2024-11-110
PRE
Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates

乌干达恶性疟原虫分离株对ganaplacide的离体敏感性和潜在抗性介质的多样性

2024-09-040
PRE
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso

布基纳法索bobo-dioulasso恶性疟原虫的离体药物敏感性和耐药性介导的遗传多态性

2024-04-031
OA
Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases

发现对人类激酶具有选择性的有效抗疟疾II型激酶抑制剂

2024-01-120
PRE
Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda

乌干达疟原虫对青蒿素部分耐药性的演变

2023-08-2467
OA
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
2023-06-154
OAAI
Structure-Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors-Part II
2023-01-113
PRE
Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors

乌干达恶性疟原虫分离株对蛋白酶体抑制剂的敏感性

2022-10-185
OA
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
2022-04-2021
OAAI
Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria
2022-03-0116
OAAI